These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 22146261)
1. [Metronomic chemotherapy in 2011: update and perspectives]. Benbrahim Z; Massard C; El Mesbahi O Bull Cancer; 2011 Dec; 98(12):1447-54. PubMed ID: 22146261 [TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy: Back to the future! André N; Padovani L; Verschuur A Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080 [TBL] [Abstract][Full Text] [Related]
4. Metronomic scheduling: the future of chemotherapy? Gasparini G Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515 [TBL] [Abstract][Full Text] [Related]
5. Metronomic dosing of chemotherapy: applications in pediatric oncology. Stempak D; Seely D; Baruchel S Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352 [TBL] [Abstract][Full Text] [Related]
7. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. Gille J; Spieth K; Kaufmann R J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746 [TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Samuel DP; Wen PY; Kieran MW Expert Opin Investig Drugs; 2009 Jul; 18(7):973-83. PubMed ID: 19548852 [TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105 [TBL] [Abstract][Full Text] [Related]
10. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy]. Qiu H; Wang GM Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810 [TBL] [Abstract][Full Text] [Related]
11. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Emmenegger U; Kerbel RS Onkologie; 2007 Dec; 30(12):606-8. PubMed ID: 18063872 [No Abstract] [Full Text] [Related]
12. The possible role of chemotherapy in antiangiogenic drug resistance. Bocci G; Loupakis F Med Hypotheses; 2012 May; 78(5):646-8. PubMed ID: 22365648 [TBL] [Abstract][Full Text] [Related]
13. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. Kerbel RS Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079 [TBL] [Abstract][Full Text] [Related]
14. Metronomic chemotherapy: teaching old drugs new tricks? Vogelzang N Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217 [No Abstract] [Full Text] [Related]
18. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic scheduling of lower dose cancer chemotherapy. Gately S; Kerbel R Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902 [TBL] [Abstract][Full Text] [Related]
20. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility. Close A Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]